Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of anaplastic lymphoma kinase (ALK) inhibitors given as monotherapy to treat advanced ALK‐rearranged non‐small cell lung cancer (NSCLC).

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cochrane Database Syst Rev
Main Authors: Cameron, Laird B, Hitchen, Nadia, Jordan, Vanessa, Manser, Renée, Solomon, Benjamin J
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2019
Teme:
Medicine General & Introductory Medical Sciences
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803015/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013453
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki